AlphaStocks
5.0
Consider Buy

Astrazeneca plc (AZN)

As of Sep 20, 2026, Astrazeneca plc (AZN) scores 5.0/10 on AlphaStocks' five-model composite, #111 of 168 Health Care stocks. At $166, AZN trades 14% below its model fair value of $193.

Health Care

ADR

$166.29

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#111out of 168 in Health Care

Is ASTRAZENECA PLC a Good Investment in 2026?

ASTRAZENECA PLC (AZN) scores 5.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates ASTRAZENECA PLC as Strong (8/9). However, the Graham model rates it Caution — Significantly above fair value. ASTRAZENECA PLC currently trades 14% below its estimated fair value of $193. ASTRAZENECA PLC ranks #111 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E25.4ROE21.9Market Cap260BDiv Yield1.9

Estimated Fair Value

$192.6314% below

Trading below estimated fair value. EPS grew 45% year-over-year. ROE of 22% signals strong profitability.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 3.2 · Stalwart

Greenblatt

Neutral

Earnings yield 4.8% · ROC >100%

Frequently Asked Questions

Is ASTRAZENECA PLC (AZN) a good investment?
As of Sep 20, 2026, Astrazeneca plc (AZN) scores 5.0/10 on AlphaStocks' five-model composite, #111 of 168 Health Care stocks. At $166, AZN trades 14% below its model fair value of $193. That score is below average, suggesting caution.
What is ASTRAZENECA PLC's Piotroski F-Score?
ASTRAZENECA PLC's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is AZN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $193, AZN appears undervalued. The stock currently trades 14% below its estimated fair value. Trading below estimated fair value. EPS grew 45% year-over-year. ROE of 22% signals strong profitability.
How does AZN compare to other Health Care stocks?
ASTRAZENECA PLC ranks #111 out of 168 stocks in the Health Care sector, placing it in the top 66% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about AZN?
AlphaStocks evaluates AZN using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.0/10.

Similar Stocks

INSPABBVINCY

Compare AZN with

AZN vs INSPABBV vs AZNAZN vs INCYAZN vs DEAZN vs NUEAZN vs PFEABT vs AZNAZN vs BSXAZN vs NVDA

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer